SILO (Silo Pharma, Inc.) Utang jangka cendhak marang modal

Silo Pharma, Inc. (SILO) is vulnerable to global political instability affecting component procurement and patent protection. Market fluctuations in the share price reflect the current indicator 0.00. The business relies on the development of innovative treatments for Alzheimer's and PTSD. The company is currently focusing on R&D for the targeted delivery of psychedelics, planning to bring new therapeutic solutions to market by 2026.

Rasio tanggungan utang jangka cendhak marang modal: Silo Pharma, Inc. (SILO) kanggo 28.04.2023 - 31.10.2026

Rincian analitis perusahaan Silo Pharma, Inc.

- kuotasi lan prakiraan analis:

Rega saham Silo Pharma|SILO - Konsensus nilai wajar

- indikator valuasi pasar bisnis:

Kapitalisasi pasar Silo Pharma Inc.|SILO - Nilai Perusahaan

- informasi kapitalisasi buku:

Aset Bersih saben Siji Saham Silo Pharma|SILO - Nilai Akuntansi Perusahaan|Rasio Nilai Pasar marang Nilai Buku silopharma.com|SILO - Gunggung Aset Perusahaan

- data liabilitas lan likuiditas perusahaan:

Total Utang marang Modal Silo Pharma, Inc.|SILO - Utang jangka dawa marang modal|Rasio utang jangka cendhak marang ekuitas Silo Pharma, Inc.|SILO - Kewajiban utang agregat|Rasio utang marang kapitalisasi buku Silo Pharma Inc.|SILO - Kewajiban jangka dawa|Utang jangka cendhak perusahaan Silo Pharma|Indikator likuiditas cepet silopharma.com

- indikator profitabilitas perusahaan lan kelipatan valuasi:

SILO - Penghasilan resik perusahaan

Pambiji fundamental:SILO Silo Pharma

To assess the financial stability of Silo Pharma, Inc. (SILO), the ratio of short-term liabilities to equity is used, measuring the proportion of debts maturing within one year in the financing structure. Given the strict FDA oversight and costly R&D developments, this chart of short-term liabilities to equity helps identify liquidity risks that are critical for maintaining patent protection and clinical trials.

Analisis pesaing Silo Pharma, Inc.